The recombinant proteins market is witnessing growth and is projected to reach USD 3,203.7 million by 2030. The increasing occurrence of numerous rare illnesses, like neutropenia, multiple sclerosis, anemia, cerebral apoplexy, and dwarfism, is driving the need for medications on the basis of recombinant proteins.
Furthermore, such agents are utilized in the advancements of novel treatments for severe chronic illnesses, such as cardiovascular diseases, cancer, viral diseases, and endocrine diseas
